» Articles » PMID: 32593561

Clinical Impact of Concomitant Tricuspid Valve Procedures During Left Ventricular Assist Device Implantation

Abstract

Background: Tricuspid regurgitation (TR) is common in patients with end-stage heart failure receiving left ventricular assist devices (LVADs), but the benefit of concomitant tricuspid valve procedures (TVPs) remains uncertain. This study examined the impact of TVP at the time of LVAD implantation on clinical outcomes and quality of life (QOL) metrics.

Methods: We included adult patients in the Interagency Registry for Mechanical Circulatory Support database with various degrees of TR who received continuous-flow LVADs from 2008 to 2017. Patients undergoing concomitant TVP were compared with those without the intervention in a stratified analysis. Descriptive analyses, survival analyses, and Andersen‒Gill hazard models were used as appropriate to examine associations with clinical and patient-centered QOL outcomes.

Results: Our analysis included 8,263 (53.1%) mild, 4,252 (33.3%) moderate, and 2,100 (13.5%) severe TR cases. TVP rate increased with severity: 8.6% of mild, 18.0% of moderate, and 43.9% of severe cases. TVP was not associated with survival benefit in cases of mild (adjusted hazard ratio [aHR]: 0.97, 95% CI: 0.79-1.19, p = 0.75), moderate (aHR: 1.03, 95% CI: 0.88-1.20, p = 0.72), or severe (aHR: 1.20, 95% CI: 0.98-1.48, p = 0.08) TR. For patients with combined moderate or severe TR, TVP was associated with increased mortality (log-rank p < 0.01, aHR: 1.13, 95% CI: 1.00-1.27, p = 0.04). After adjusting for TR severity, TVP was associated with increased risk of bleeding, arrhythmia, and stroke (p < 0.01 each) and no improvements in QOL (p > 0.05).

Conclusions: TVP at the time of LVAD implantation was not associated with either improved survival or QOL, and there were associations with increased risk of adverse events among patients with moderate and severe TR.

Citing Articles

Recent Developments in Ventricular Assist Device Therapy.

Moctezuma-Ramirez A, Mohammed H, Hughes A, Elgalad A Rev Cardiovasc Med. 2025; 26(1):25440.

PMID: 39867170 PMC: 11760545. DOI: 10.31083/RCM25440.


Special Considerations for Advanced Heart Failure Surgeries: Durable Left Ventricular Devices and Heart Transplantation.

Akbar A, Zhou A, Wang A, Feng A, Rizaldi A, Ruck J J Cardiovasc Dev Dis. 2024; 11(4).

PMID: 38667737 PMC: 11050210. DOI: 10.3390/jcdd11040119.


Concomitant tricuspid valve surgery in patients undergoing left ventricular assist device: a systematic review and meta-analysis.

Luo Y, Leng J, Shi R, Jiang Y, Chen D, Wu Q Int J Surg. 2024; 110(5):3039-3049.

PMID: 38348836 PMC: 11093502. DOI: 10.1097/JS9.0000000000001189.


Pulmonary Vascular Resistance to Predict Right Heart Failure in Patients Undergoing Left Ventricular Assist Device Implantation.

Schramm R, Kirchner J, Ibrahim M, Rojas S, Morshuis M, Rudolph V J Clin Med. 2024; 13(2).

PMID: 38256596 PMC: 10816947. DOI: 10.3390/jcm13020462.


Does concomitant tricuspid valve intervention at the time of left ventricular assist device placement for patients with significant tricuspid regurgitation lead to improved outcomes compared to isolated left ventricular assist device placement?.

Mitra A, Castleberry A, Urban M, Siddique A Interdiscip Cardiovasc Thorac Surg. 2024; 38(2).

PMID: 38216526 PMC: 10850842. DOI: 10.1093/icvts/ivae005.